Genelife Clinical Research Pvt. Ltd.

Genelife Clinical Research is a trusted Contract Research Organization (CRO) delivering comprehensive Phase I–IV clinical trial services for pharmaceutical, biotechnology, and medical device companies. Headquartered in Mumbai, we provide end-to-end clinical research solutions including clinical operations, regulatory affairs, data management, pharmacovigilance, and medical writing, supported by a global presence across the USA, UK, and Europe. We also offer real-world evidence (RWE) studies and healthcare market research to support product lifecycle decision-making.

[genelife]

There is a sentence that has ended more nutraceutical businesses than any reformulation or supply chain failure. It usually reads something like: "Clinically proven to treat joint inflammation." Or: "Reduces blood sugar in diabetic patients." Or: "Prevents cold and flu." Each of these crosses the same line — from a permissible nutraceutical claim into therapeutic drug territory. When that line is crossed, the product is no longer a nutraceutical. It is, in regulatory terms, an unapproved drug. In India that means CDSCO jurisdiction. In the US it means FDA's drug division. The consequences — recall, license suspension, prosecution — are not proportionate to what was often a careless word choice rather than deliberate deception. Understanding the four categories of nutraceutical health claims — nutrient content, structure/function, health claims, and general wellbeing — and precisely where the boundaries between them lie is not a compliance exercise. It is a commercial survival skill. We have written a detailed guide to the claim categories and substantiation procedures across India (FSSAI), the US (FDA and FTC), and the EU (EFSA) — including the specific procedural steps, documentation requirements, and the practical checklist every manufacturer needs before a claim goes on the pack.

#Nutraceuticals #ClaimSubstantiation #FSSAI #FDA #FTC #EFSA #RegulatoryCompliance #ClinicalResearch #Genelife

The Claim You Make Is the Line You Must Not Cross: A Practical Guide to Nutraceutical Claim Substantiation

Every nutraceutical product lives and dies by what it claims. "Supports heart health.

[genelife]

The Evidence GAP Analysis: Why Every Nutraceutical Development Program Should Start Here

Genelife, Clinical Research, GCP, Medical Device, Patient Recruitment, Asthma, Oncology, Ophthalmology, Clinical Trials, Cancer, tuberculosi

Regulators in the US, EU, Australia, and UK are all moving in the same direction on nutraceutical health claims.

The era of marketing on plausibility and tradition alone is ending. Clinical evidence — rigorous, human, controlled — is becoming the price of credible market positioning.

The question for international nutraceutical companies isn't whether to generate that evidence. It's how to do it at a cost and speed that makes commercial sense.

That's where India comes in.

The same randomized controlled trial that costs USD 1–2 million in the US or Western Europe can be conducted in India — to the same ICH GCP standards, generating data acceptable to FDA, EMA, and TGA — at 30 to 50 percent of that cost. With faster ethics approvals, faster recruitment, and a patient population that is uniquely relevant for metabolic, inflammatory, and nutritional intervention studies.

The companies that are ahead of the regulatory curve are already doing this.

Monday's article breaks down the evidence gap, why it's closing, and why India is where international nutraceutical companies are choosing to close it.

[genelife]

The Evidence GAP Analysis: Why Every Nutraceutical Development Program Should Start Here

Genelife, Clinical Research, GCP, Medical Device, Patient Recruitment, Asthma, Oncology, Ophthalmology, Clinical Trials, Cancer, tuberculosi

Most nutraceutical clinical programs begin with a study design. They should begin with a question: what evidence already exists, what does it actually prove, and what is missing? This is the evidence GAP analysis — and its absence is one of the most reliable predictors of expensive, avoidable mistakes in nutraceutical development. The pattern is consistent. A brand has a product. The product has an ingredient with published literature. The brand assumes the literature supports their claim. They proceed to marketing or regulatory submission. They discover — from a regulator, a retail buyer, or a legal challenge — that the literature does not support the specific claim at the specific dose in the specific formulation they are selling. A GAP analysis conducted before any of those decisions would have identified the discrepancy in weeks, not after months of investment and market commitment. We've written a detailed breakdown of what a rigorous nutraceutical evidence GAP analysis actually involves — the five dimensions of evidence quality it evaluates, the most common gaps it finds, and why it changes the economics of every development decision that follows.

[genelife]

This week is World Breastfeeding Week — and it is a good moment to acknowledge something the clinical research community does not discuss often enough.

The science behind breastfeeding is still evolving. Human milk science, maternal nutrition, neonatal microbiome development, the immunological properties of colostrum — these are active areas of clinical research with significant evidence gaps that directly affect how millions of mothers and newborns are supported around the world.

At Genelife, we work across maternal health, neonatal care, nutraceutical clinical evidence, and women's health research. The intersection of good science and early-life health outcomes is one of the most important frontiers in clinical research — and one where the evidence base still has a long way to go.

To every mother navigating those first weeks with a newborn: the science is on your side, and more of it is being built every day.

[genelife]

On World Lung Cancer Day, one statistic stands out above all others:

LungCancer kills more people globally each year than colon, breast, and prostate cancer combined.

And yet it remains one of the most underfunded and stigmatised cancers — partly because of the persistent assumption that it only affects smokers. It doesn't. Non-smokers account for a significant share of diagnoses, linked to radon exposure, air pollution, secondhand smoke, and genetic factors that have nothing to do with cigarettes.

The single most impactful weapon we have is early detection. When caught early, survival rates improve dramatically. When caught late — as most cases still are — options narrow significantly.

At Genelife Clinical Research, we are proud to support oncology clinical research that brings better diagnostics and treatments to patients who need them. Every clinical trial we support is a step toward better outcomes for real people living with this disease.

To everyone affected by lung cancer — patients, families, caregivers, and researchers — today is for you.

[genelife]

At Genelife Clinical Research, we help companies generate scientifically credible evidence through GCP-compliant clinical studies designed for global regulatory and commercial requirements. Our capabilities include: ✔ HRIPT (Human Repeat Insult Patch Test) ✔ Dermatological & Skin Safety Testing ✔ SPF & UVA Testing ✔ Anti-ageing & Skin Rejuvenation Studies ✔ Moisturisation & Skin Barrier Assessment ✔ Skin Brightening & Pigmentation Studies ✔ Hair & Scalp Clinical Evaluation ✔ Vaginal Microbiome & qPCR Studies ✔ Gynaecologist-Supervised Intimate Care Testing ✔ Marketing Claim Substantiation & Clinical Study Reports Whether you are developing innovative skincare formulations, botanical cosmetics, intimate hygiene products, or advanced cosmeceuticals, scientifically validated clinical evidence helps build regulatory confidence, retailer acceptance, and consumer trust.

Cosmeceutical Clinical Testing in India

What Is Cosmeceutical Clinical Testing? Cosmeceutical clinical testing is the systematic generation of clinical evidence to substantiate the

[genelife]

The Claim Problem in Cosmeceuticals: Why Clinical Evidence Has Become the Industry's Most Important Competitive Asset

Why Cosmeceutical Claims Are Under Greater Scrutiny Than Ever Before

"Clinically proven." "Dermatologically tested." "Microbiome-friendly." "Gynaecologically approved." These are some of the most common claims in cosmetics and personal care. They are also some of the most poorly substantiated — because the bar required to make them defensibly has risen significantly in recent years, while many brands are still relying on ingredient safety data or in vitro tests that no longer satisfy regulatory expectations. The EU Cosmetics Regulation requires documented claim substantiation in every product information file. Advertising standards bodies in India, the UK, and across the EU are reviewing cosmetic claims with increasing rigour. Major retail chains require clinical study reports as part of product listing qualification. The brands that will own the best shelf positions in the next five years are the ones building rigorous clinical evidence now — not after a regulatory challenge forces them to. We've written a detailed guide to what cosmeceutical clinical evidence actually requires — for skin safety, efficacy, microbiome claims, and intimate care — and why India has become one of the most strategically valuable locations to generate it.

[genelife]

Real World Evidence & Market Research: How Genelife CRO India Bridges the Gap Between Clinical Trials and Real-World Impact

This article explains what RWE and market research services entail, why they matter, and how Genelife's approach delivers actionable evidenc

Randomised controlled trials prove efficacy under controlled conditions. But what happens when your drug meets real patients — with comorbidities, polypharmacy, and diverse lifestyles?

[genelife]

Real World Evidence & Market Research: How Genelife CRO India Bridges the Gap Between Clinical Trials and Real-World Impact

This article explains what RWE and market research services entail, why they matter, and how Genelife's approach delivers actionable evidenc

Is your clinical trial data telling the whole story?

Randomised controlled trials prove efficacy under controlled conditions. But what happens when your drug meets real patients — with comorbidities, polypharmacy, and diverse lifestyles?

That's where Real World Evidence comes in.

At Genelife Clinical Research, we help global pharma and biotech companies bridge the gap between clinical trial results and real-world outcomes — through patient registries, observational studies, disease burden mapping, and market research that captures how treatments actually perform in practice.

India offers a unique advantage for RWE generation — 1.4 billion people, extraordinary disease diversity, and 40–60% lower costs than the US or Europe. We've covered everything you need to know in our latest article

[genelife]

Bioavailability and Bioequivalence Studies: The Science, the Strategy, and What Makes Them Work

Understanding the Difference: Bioavailability vs. Bioequivalence

BA/BE studies are not the simple, low-risk end of pharmaceutical clinical research.

They are scientifically precise, operationally demanding, and highly sensitive to design and execution errors. And because the regulatory acceptance criterion — a 90% confidence interval for AUC and Cmax within 80–125% — is fixed and statistical, there is no room to compensate for a poorly designed study with a well-written report.

The most common and costly failures:

→ Variability assumptions that were too optimistic — resulting in an underpowered study that cannot achieve the required confidence interval → Site selection decisions made on cost rather than capability — generating data quality issues that regulators query → Bioanalytical method validation gaps that undermine the credibility of the entire PK dataset → Protocol deviations during execution that require explanation and, in some cases, invalidate individual subject data

In a competitive generics market where first-to-file and first-to-market advantages are measured in months, a failed pivotal BE study is not a minor setback. It is a significant competitive loss.

[genelife]

India's Botanical Heritage Meets Global Clinical Standards: The Case for India-Based Nutraceutical Research

Discover how India is becoming preferred destination for nutraceutical clinical research, botanical clinical trials, and real-world evidence

The traditional knowledge, the raw material supply chains, the phytochemical expertise, and the processing infrastructure are concentrated in India to a degree no other country approaches.

[genelife]

On Monday we published an article on the constraints in medical device clinical trials.

The one that gets underestimated most consistently:

Operator dependency.

In a pharmaceutical trial, you randomize patients. The drug is the same regardless of who prescribes it.

In a device trial, you also have to manage — implicitly — the randomization of operator skill. And you can't. A stent deployed by an experienced interventional cardiologist at a high-volume center produces different outcomes than the same stent deployed by a less experienced operator. A surgical robot's performance depends on technique, intraoperative decisions, and learning curve effects that vary systematically across operators.

The consequence: trial outcomes that reflect operator skill as much as device performance. Evidence that is not reproducible in the broader clinical community. Pivotal trial results that look different from post-market registry data — not because the device changed, but because the operator base did.

Managing this requires explicit design choices. Pre-defined operator qualification criteria. Structured proctoring. Centre-level outcome monitoring. Pre-specified analysis of outcomes by operator volume.

The trials that get this right produce evidence that is both more scientifically honest and more regulatory-credible.

#MedicalDevices #ClinicalTrials #DeviceResearch #ClinicalResearch #EUMDR #FDA #CDSCO #CRO

The Constraints in Medical Device Clinical Trials: Why Device Research Is Harder Than It Looks

Genelife Expertise in Medical Device Clinical Trials

[genelife]

India isn't one epidemiological environment. It's at least three.

A still-substantial infectious disease burden — dengue, TB, vector-borne disease — that requires classical surveillance methodology. A rapidly accelerating non-communicable disease epidemic — diabetes, cardiovascular disease, CKD — that looks meaningfully different than it did five years ago. And a population scale and genetic diversity that makes safety signal detection and subgroup analysis possible in ways smaller markets simply can't support.

#Epidemiology #DiseaseSurveillance #RealWorldEvidence #Pharmacovigilance #ClinicalResearch #India #CRO #PublicHealth

[genelife]

Medicinal Plants in Health Management: Ancient Wisdom, Modern Evidence

Medicinal plants in health management combining Ayurvedic botanicals with modern clinical research and evidence-based healthcare.

India's medicinal plant tradition documented cardiovascular disease management in 500 BCE.

It identified cognitive enhancers — Brahmi, Ashwagandha — centuries before the term nootropic existed.

It described hepatoprotective herbs whose mechanisms modern pharmacology is still characterizing.

The knowledge was always there. What's been missing is the clinical evidence that meets today's regulatory standards.

[genelife]

The Constraints in Medical Device Clinical Trials: Why Device Research Is Harder Than It Looks

Genelife Expertise in Medical Device Clinical Trials

Medical device clinical trials face constraints pharmaceutical trials don't: → No placebo control — you can't give someone a sham stent → No reversibility — an implanted device cannot be discontinued → No operator standardization — skill level varies and cannot be randomized → No stable product — the device iterates faster than the trial can report → No simple endpoint — device performance ≠ patient outcomes Each of these is a structural feature of device research, not a problem that better methodology will eliminate. The clinical programs that succeed are the ones designed by people who understand this — and build their strategy around it from day one.

[genelife]

Medicinal Plants in Health Management: Ancient Wisdom, Modern Evidence

Medicinal plants in health management combining Ayurvedic botanicals with modern clinical research and evidence-based healthcare.

India's medicinal plant tradition documented cardiovascular disease management in 500 BCE.

It identified cognitive enhancers — Brahmi, Ashwagandha — centuries before the term nootropic existed.

It described hepatoprotective herbs whose mechanisms modern pharmacology is still characterizing.

The knowledge was always there. What's been missing is the clinical evidence that meets today's regulatory standards.

[genelife]

India's Botanical Heritage Meets Global Clinical Standards: The Case for India-Based Nutraceutical Research

Discover how India is becoming preferred destination for nutraceutical clinical research, botanical clinical trials, and real-world evidence

There's a paradox at the center of the global botanical nutraceutical market.

The ingredients generating the most commercial interest internationally — ashwagandha, curcumin, boswellia, brahmi, moringa — have their deepest roots in India. The traditional knowledge, the raw material supply chains, the phytochemical expertise, and the processing infrastructure are concentrated in India to a degree no other country approaches.

Yet most of the clinical evidence for these ingredients has been generated in Western research settings — often with Indian-sourced material, studied in Western populations, under Western regulatory frameworks.

That's changing. And this article makes the case for why India is actually the right place to generate clinical evidence for these ingredients — not just the cheapest place.

The ingredient expertise is here. The raw material supply chains are here. The patient populations most relevant to adaptogen, metabolic, and inflammatory research are here. And an internationally credible clinical research infrastructure that generates data acceptable to FDA, EMA, and TGA is here too.

For international nutraceutical companies building clinical programs around botanical ingredients, India isn't just a cost play. It's the location where everything aligns.

#Nutraceuticals #Botanicals #Ashwagandha #Ayurveda #ClinicalResearch #India #CRO #FDA #EMA #DietarySupplements